Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLESTID vs COLESEVELAM HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.
Adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Digoxin toxicity (off-label),Hyperthyroidism (off-label),Pseudomembranous colitis (off-label)
Adjunctive therapy to diet and exercise for reduction of elevated LDL cholesterol in adults with primary hyperlipidemia,Monotherapy or combination therapy for homozygous familial hypercholesterolemia,Adjunctive therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Pediatric primary hyperlipidemia
5-10 g orally once or twice daily, maximum 30 g/day.
3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not applicable as colesevelam is not absorbed; it acts locally in the gastrointestinal tract.
Not absorbed systemically; not metabolized; excreted unchanged in feces.
Colesevelam is not systemically absorbed (<0.05%) and undergoes negligible metabolism.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Colesevelam is not absorbed systemically; it is excreted unchanged in the feces via biliary elimination. No renal excretion occurs.
Not significantly absorbed; binding not applicable
0% (not absorbed; no systemic protein binding).
Not applicable (non-absorbed; confined to gastrointestinal lumen)
Not applicable; drug is not systemically absorbed and remains confined to the gastrointestinal lumen.
Oral: <0.05% (negligible systemic absorption)
<0.1% after oral administration; essentially not absorbed.
No specific dosage adjustment required for renal impairment; use with caution in patients with renal dysfunction due to potential for hyperchloremic metabolic acidosis.
No dose adjustment required for renal impairment; not systemically absorbed.
No specific dosage adjustment required for hepatic impairment; use with caution in patients with pre-existing gastrointestinal disorders.
No dose adjustment required for hepatic impairment.
Safety and efficacy not established; limited data suggest 5-10 g daily in divided doses for children aged 12-18 years.
Not approved for pediatric patients; safety and efficacy not established.
No specific dosage adjustment; monitor for constipation and gastrointestinal adverse effects; initiate at low end of dosing range.
No specific dose adjustment; use with caution due to potential for constipation and gastrointestinal obstruction.
No FDA black box warning.
No FDA black box warning.
May cause fecal impaction, especially in patients with hemorrhoids or constipation.,May interfere with absorption of fat-soluble vitamins (A, D, E, K).,May reduce absorption of other drugs; take other medications at least 1 hour before or 4-6 hours after colestipol.,Use with caution in patients with bleeding tendencies or with impaired hepatic function.,Hypertriglyceridemia may occur.
May cause hypertriglyceridemia (monitor triglycerides),Risk of fat-soluble vitamin deficiency (Vitamins A, D, E, K) with prolonged use,May reduce absorption of: oral contraceptives, cyclosporine, warfarin, thyroid hormone, and other drugs (administer 4 hours before or after Colesevelam),Patients with hemorrhoids or history of severe GI obstruction risk,May cause constipation, dyspepsia, and abdominal pain
Complete biliary obstruction,Hypersensitivity to colestipol or any component of the formulation
Bowel obstruction or history of bowel obstruction,Hypertriglyceridemia-induced pancreatitis,Elevated serum triglycerides >500 mg/d L,Hypersensitivity to colesevelam or any component
Colestipol may bind to fat-soluble vitamins (A, D, E, K) and decrease their absorption. Take vitamin supplements at least 1 hour before or 4 hours after colestipol. High-fat meals may reduce binding efficacy; take with meals containing moderate fat.
Take with meals to enhance bile acid binding. Avoid high-fat meals that may reduce efficacy. Colesevelam may interfere with absorption of fat-soluble vitamins (A, D, E, K); consider supplementation if long-term use. Grapefruit juice has no documented interaction.
FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefore, fetal risk is considered minimal. Trimester-specific risks: First trimester: No known risk due to lack of absorption. Second and third trimesters: Potential for decreased absorption of fat-soluble vitamins and folate, which may affect fetal development. Vitamin K deficiency may increase neonatal bleeding risk.
Colesevelam hydrochloride is not systemically absorbed (<0.05% oral bioavailability). No fetal risk is expected. No adequate and well-controlled studies in pregnant women. Based on animal studies, no evidence of harm at doses up to 1.5 times human dose. Insufficient data for first trimester; however, given negligible absorption, teratogenic risk is considered negligible across all trimesters.
Colestipol is not absorbed systemically, thus is not expected to be excreted into breast milk. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for potential gastrointestinal effects secondary to maternal use.
Colesevelam is not absorbed systemically; therefore, excretion into breast milk is negligible. M/P ratio: not applicable. Considered compatible with breastfeeding by most sources.
No dose adjustment required due to lack of systemic absorption. However, ensure adequate nutritional status: monitor fat-soluble vitamin supplementation (A, D, E, K) and folate; increase interval between colestipol and prenatal vitamins/food to 1 hour before or 4 hours after.
No dosing adjustment is necessary. Colesevelam's pharmacokinetics are unaffected by pregnancy due to negligible systemic absorption. Dose should be based on clinical response to hyperlipidemia. Standard adult dosing: 3 tablets (625 mg each) twice daily or 6 tablets once daily with food and liquid.
Colestipol is a bile acid sequestrant; administer with meals to bind bile acids. Monitor for constipation and increase fluid/fiber intake. Reduce doses of other medications by at least 1 hour before or 4 hours after colestipol. May increase triglyceride levels; monitor lipids. Use with caution in patients with renal impairment.
Colesevelam is a bile acid sequestrant that reduces LDL-C and improves glycemic control in type 2 diabetes. Administer with meals to maximize bile acid binding. Monitor triglycerides as levels may increase. Separate dosing from other medications (e.g., levothyroxine, warfarin) by at least 4 hours to avoid reduced absorption. Can be mixed with water, fruit juice, or soft foods.
Take exactly as prescribed, usually once or twice daily with food and a full glass of water.,Do not take other medications within 1 hour before or 4 hours after colestipol.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Inform your doctor if you have a history of hemorrhoids or digestive problems.,Keep out of reach of children; store at room temperature.
Take this medication with a meal and at least 4 hours after any other medications.,Mix powder with 4-8 ounces of water, fruit juice, or soft food (e.g., applesauce) and consume within 24 hours.,Do not take without food; it may cause stomach upset.,Common side effects include constipation, gas, and indigestion; drink plenty of fluids and increase fiber intake.,This medication can increase triglyceride levels; your doctor will monitor your blood.,Inform your doctor if you have a history of pancreatitis or gallbladder disease.,Keep out of reach of children and store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLESTID vs COLESEVELAM HYDROCHLORIDE, answered by our medical review team.
COLESTID is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.. COLESEVELAM HYDROCHLORIDE is a Bile Acid Sequestrant that works by Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLESTID and COLESEVELAM HYDROCHLORIDE depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLESTID is: 5-10 g orally once or twice daily, maximum 30 g/day.. The standard adult dose of COLESEVELAM HYDROCHLORIDE is: 3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLESTID and COLESEVELAM HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLESTID is classified as Category C. FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefor. COLESEVELAM HYDROCHLORIDE is classified as Category A/B. Colesevelam hydrochloride is not systemically absorbed (<0.05% oral bioavailability). No fetal risk is expected. No adequate and well-controlled studies in pregnant women. Based on. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.